In this interview, CEO Sara Barrington of Verici DX – an advanced medical diagnostics firm focusing on the global kidney transplant market - takes me through:
00:00 Verici's unique technology and market opportunity
03:30 Significance of last week’s excellent news that the company’s flagship blood test Tutivia has been granted US medicare coverage.
11:30 Relationship with Thermo Fisher Scientific (re pre-graft Clarava/PTRA test)
14:50 Update on Protega diagnostics
16:40 Next steps & outlook
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
